Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Adcetris Brentuximab vedotin Systemic Anaplastic Large Cell Lymphoma Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Hodgkin Lymphoma Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Advanced Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Alimta Pemetrexed Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Arzerra Ofatumumab Chronic Lymphocytic Leukemia Do not reimburse Complete
Avastin (with capecitabine) Bevacizumab Metastatic Colorectal Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Bosulif Bosutinib Chronic Myeloid Leukemia Reimburse with clinical criteria and/or conditions Complete
Erbitux Cetuximab Metastatic Colorectal Cancer Do not reimburse Complete